Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Sunday, setting a price target of $52, which is approximately 15.45% above the present share price of $45.04.
Divan expects SAGE Therapeutics to post earnings per share (EPS) of -$1.83 for the fourth quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $72.45.
The analysts price targets range from a high of $100 to a low of $50.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.64 million and a net profit of -$108.02 million. The company's market cap is $2.65 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.5% and a 48.30% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.